Stocktoria
Replimune Group, Inc. REPL
Replimune Group, Inc. (REPL) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.665 |
| Retained earnings / assets | -3.798 |
| EBIT / assets | -0.962 |
| Equity / liabilities | 1.0 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| REPL | Replimune Group, Inc. | 1/9 | -13.44 | — | — |
| AMGN | AMGEN INC | 6/9 | 0.14 | 25.1 | +10% |
| GILD | GILEAD SCIENCES, INC. | 7/9 | 3.28 | 18.7 | +2.4% |
| BIIB | BIOGEN INC. | 4/9 | — | 24.7 | +2.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | 5/9 | 6.21 | 35.4 | +21.4% |
| EXEL | EXELIXIS, INC. | 6/9 | 7.69 | 17.6 | +7% |
| QGEN | QIAGEN N.V. | 7/9 | 5.06 | 19.1 | +5.7% |
About Replimune Group, Inc.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
FAQ
Is REPL financially healthy?
Replimune Group, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does REPL pay a dividend?
No, Replimune Group, Inc. does not currently pay a dividend.
How profitable is REPL?
In FY2026, Replimune Group, Inc. had a return on equity of -188.9%.
What is the analyst price target for REPL?
The average Wall-Street price target for Replimune Group, Inc. is $7.67, about 49.7% below the recent price, from 6 analysts (consensus: hold).
Is REPL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Replimune Group, Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.